Latest News for BIAF
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead?
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AAAAI--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BAMC--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
Shares of bioAffinity Technologies, Inc. (NASDAQ: BIAF - Get Free Report) dropped 13.8% during mid-day trading on Monday. The stock traded as low as $0.90 and last traded at $0.9305. Approximately 215,677 shares traded hands during trading, a decline of 20% from the average daily volume of 270,549 shares. The stock had previously closed at
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIAF.
U.S. House Trading
No House trades found for BIAF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.